


Figure S1. INFAST study design.

Figure S1



NOTE: Data from Week 28 through Week 52 are not reported in this manuscript.

ASAS, Assessments in Ankylosing Spondylitis; IFX, infliximab; INFAST, Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial; NPX, naproxen; PBO, placebo; WK, week.